Can-Fite BioPharma (CANF) CF101 Does Not Achieve Primary Endpoint in Phase II/III Trial
Tweet Send to a Friend
Can-Fite BioPharma Ltd. (NYSE: CANF) announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
